公开(公告)号：US12049512B2

公开(公告)日：2024-07-30

申请号：US16921154

申请日：2020-07-06

Applicant: GENMAB B.V.

Inventor： Paul Parren ,  Frank Beurskens ,  Rob N. De Jong ,  Aran Frank Labrijn ,  Janine Schuurman

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/36 ,  C12P21/08 ,  A61K39/00 ,  C07K1/00

CPC classification number: C07K16/2896 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/36 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92

Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.

公开(公告)号：US20230089196A1

公开(公告)日：2023-03-23

申请号：US17800740

申请日：2021-02-19

Applicant: Genmab B.V.

Inventor： Ewald T.J. VAN DEN BREMER ,  Sipke SANGERS ,  Demelza WILLEMSZ ,  Richard G. HIBBERT ,  Rob N. DE JONG ,  Søren Skov JENSEN ,  Emil POULSEN

IPC: G01N33/68

Abstract: The invention relates to methods for the quantification of glycoproteins in a sample, comprising quantifying said glycoproteins by comparison with an internal standard, wherein said internal standard comprises variant forms of said glycoproteins, wherein said variant forms contain only core Asn-linked GlcNAc moieties.

公开(公告)号：US11180572B2

公开(公告)日：2021-11-23

申请号：US14413178

申请日：2013-07-05

Applicant: GENMAB B.V.

Inventor： Rob N. De Jong ,  Frank Beurskens ,  Paul Parren ,  Aran Frank Labrijn ,  Janine Schuurman ,  Arjen Vlug ,  Sandra Verploegen

IPC: C07K16/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  C07K16/40 ,  C07K16/32 ,  C07K16/10 ,  C07K16/36 ,  C07K16/12 ,  A61K39/00

Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

公开(公告)号：US20210324096A1

公开(公告)日：2021-10-21

申请号：US17108373

申请日：2020-12-01

Applicant: GENMAB B.V.

Inventor： Marije OVERDIJK ,  Kristin STRUMANE ,  Rik RADEMAKER ,  Esther BREIJ ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C12N15/62

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20210238296A1

公开(公告)日：2021-08-05

申请号：US17051205

申请日：2019-05-03

Applicant: GENMAB B.V.

Inventor： Rob DE JONG ,  Frank BEURSKENS ,  Simone OOSTINDIE ,  Aran Frank LABRIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Bart-Jan DE KREUK

IPC: C07K16/28 ,  A61K45/06

Abstract: Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.

公开(公告)号：US20210163619A1

公开(公告)日：2021-06-03

申请号：US16921154

申请日：2020-07-06

Applicant: GENMAB B.V.

Inventor： Paul PARREN ,  Frank BEURSKENS ,  Rob N. DE JONG ,  Aran Frank LABRIJN ,  Janine SCHUURMAN

IPC: C07K16/28 ,  C07K16/36 ,  C07K16/00

Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.

公开(公告)号：US20240141057A1

公开(公告)日：2024-05-02

申请号：US18461910

申请日：2023-09-06

Applicant: GENMAB B.V.

Inventor： Claudine Brigitte Fernande Vermot-Desroches ,  Olivier Frédéric Subiger ,  Laurence Françoise Jeanne-Marie Bourdin

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  A61K2039/507

Abstract: Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.

公开(公告)号：US20220411529A1

公开(公告)日：2022-12-29

申请号：US17774333

申请日：2020-11-06

Applicant: GENMAB B.V.

Inventor： Rob DE JONG ,  Frank BEURSKENS ,  Gijs ZOM ,  Janine SCHUURMAN ,  Xiaoguang XUE

IPC: C07K16/28

Abstract: The invention relates to combination therapy involving two or more antibodies, wherein the Fc regions of the two antibodies have been modified such that hetero-oligomerization between the antibodies is strongly favored over self-oligomerization when antibodies are bound to their corresponding target antigens and such that hetero-oligomerization-independent effector functions of one or both antibodies are eliminated or strongly reduced. The invention also relates to antibodies, compositions, and kits suitable for use in the combination therapy of the invention.

公开(公告)号：US20220332801A1

公开(公告)日：2022-10-20

申请号：US17534712

申请日：2021-11-24

Applicant: GENMAB B.V.

Inventor： Annemarie KUIPERS ,  Kok VAN KESSEL ,  Frank BEURSKENS ,  Rob DE JONG ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN ,  Jos VAN STRIJP ,  Suzan ROOIJAKKERS

IPC: C07K16/12 ,  A61P31/04

Abstract: The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of infectious diseases using these compositions

公开(公告)号：US20210107988A1

公开(公告)日：2021-04-15

申请号：US16963701

申请日：2019-01-24

Applicant: GENMAB B.V.

Inventor： Simone OOSTINDIE ,  Andreas HOLLENSTEIN ,  Frank BEURSKENS ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Rob DE JONG

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to combination therapy involving two or more Fc region-containing antigen-binding polypeptides, such as antibodies, wherein the polypeptides have been modified such that hetero-oligomerization between the polypeptides is strongly favored over homo-oligomerization when the polypeptides are bound to their corresponding target antigens. The invention also relates to polypeptides, compositions, kits and devices suitable for use in the combination therapy of the invention.